NO981272L - Humanisert anti-human-Fas-antistoff - Google Patents

Humanisert anti-human-Fas-antistoff

Info

Publication number
NO981272L
NO981272L NO981272A NO981272A NO981272L NO 981272 L NO981272 L NO 981272L NO 981272 A NO981272 A NO 981272A NO 981272 A NO981272 A NO 981272A NO 981272 L NO981272 L NO 981272L
Authority
NO
Norway
Prior art keywords
humanized anti
human fas
fas antibody
antibodies
provides
Prior art date
Application number
NO981272A
Other languages
English (en)
Other versions
NO981272D0 (no
Inventor
Nobufusa Serizawa
Hideyuki Haruyama
Tohru Takahashi
Kaori Nakahara
Shin Yonehara
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of NO981272D0 publication Critical patent/NO981272D0/no
Publication of NO981272L publication Critical patent/NO981272L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Oppfinnelsen tilveiebringer humaniserte anti-human-Fas-antistoffer som er i stand til å indusere apoptose i celler som uttrykker Fås, og som kan anvendes ved behandling av autoimmun- sykdom og kronisk reumatoid artritt. I tillegg tilveiebringer oppfinnelsen DNA som koder for de variable områdene i H- og L-kjeden i slike antistoffer, og fremgangsmåter for humanisering av an- tistoffer.
NO981272A 1997-03-21 1998-03-20 Humanisert anti-human-Fas-antistoff NO981272L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP6793897 1997-03-21

Publications (2)

Publication Number Publication Date
NO981272D0 NO981272D0 (no) 1998-03-20
NO981272L true NO981272L (no) 1998-09-22

Family

ID=13359383

Family Applications (1)

Application Number Title Priority Date Filing Date
NO981272A NO981272L (no) 1997-03-21 1998-03-20 Humanisert anti-human-Fas-antistoff

Country Status (15)

Country Link
EP (1) EP0866131A3 (no)
KR (1) KR19980080514A (no)
AR (1) AR012148A1 (no)
AU (1) AU736287B2 (no)
BR (1) BR9800937A (no)
CA (1) CA2232828A1 (no)
CZ (1) CZ85898A3 (no)
HU (1) HUP9800613A3 (no)
ID (1) ID20065A (no)
IL (1) IL123756A0 (no)
NO (1) NO981272L (no)
NZ (1) NZ330004A (no)
PL (1) PL325457A1 (no)
TR (1) TR199800517A2 (no)
ZA (1) ZA982371B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
EP1087993B1 (en) * 1998-06-18 2008-04-02 Imed Ab Fas peptides and antibodies for modulating apoptosis
AU757961B2 (en) * 1998-09-30 2003-03-13 Sankyo Company Limited Anti-Fas antibodies
AU2004233486B2 (en) * 1999-01-11 2007-09-13 Leadd B.V. Use of apoptosis inducing agents in the treatment of (auto)immune diseases
EA200100770A1 (ru) * 1999-01-11 2002-02-28 Леадд Б.В. Применение агентов, индуцирующих апоптоз, в лечении (ауто)имунных заболеваний
MXPA01012206A (es) * 1999-05-24 2002-06-21 Sankyo Co Composiciones farmaceuticas que contienen anticuerpo anti-fas.
DE60334364D1 (de) * 2002-02-21 2010-11-11 Univ California Behandlungsverfahren unter verwendung von anti-cd22-antikörpern
AU2003234003A1 (en) * 2002-05-17 2003-12-02 Fusion Antibodies Limited Treatment of cancer by the use of anti fas antibody
GB0306618D0 (en) * 2003-03-22 2003-04-30 Univ Newcastle Antibody
WO2007103469A2 (en) 2006-03-06 2007-09-13 Aeres Biomedical Ltd. Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US8030026B2 (en) * 2009-02-24 2011-10-04 Abbott Laboratories Antibodies to troponin I and methods of use thereof
CA3004830A1 (en) 2015-11-11 2017-05-18 Opi Vi- Ip Holdco Llc Composition and methods for anti-tnfr2 antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
ATE255131T1 (de) * 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
EP0723556A4 (en) * 1993-10-14 2003-03-19 Immunex Corp FAS ANTAGONISTS AND THEIR APPLICATIONS
CA2158822C (en) * 1994-09-27 2008-12-23 Kusuki Nishioka Therapeutic agent for rheumatic disease
AU724579B2 (en) * 1996-04-01 2000-09-28 Sankyo Company Limited Anti-Fas recombinant antibodies and DNA therefor

Also Published As

Publication number Publication date
PL325457A1 (en) 1998-09-28
TR199800517A3 (tr) 1998-10-21
IL123756A0 (en) 1998-10-30
HUP9800613A2 (hu) 1999-02-01
BR9800937A (pt) 2000-01-11
NZ330004A (en) 1998-10-28
NO981272D0 (no) 1998-03-20
TR199800517A2 (xx) 1998-10-21
AR012148A1 (es) 2000-09-27
EP0866131A2 (en) 1998-09-23
CZ85898A3 (cs) 1998-10-14
EP0866131A3 (en) 1999-12-15
AU736287B2 (en) 2001-07-26
HU9800613D0 (en) 1998-05-28
HUP9800613A3 (en) 2001-04-28
ID20065A (id) 1998-09-24
CA2232828A1 (en) 1998-09-21
KR19980080514A (ko) 1998-11-25
ZA982371B (en) 1998-09-28
AU5937598A (en) 1998-10-15

Similar Documents

Publication Publication Date Title
WO1996020277A3 (en) Recombinant monoclonal anti-idiotype antibody 3h1 sequences relating to human carcinoembryonic antigen
EP0765172A4 (en) FOR E-SELECTIN AND P-SELECTIN-SPECIFIC CROSS-REACTIVE MONOCLONAL ANTIBODIES
IL263573A (en) Anti-ngf antibodies and methods of using them
EP0867451A3 (en) Monoclonal antibodies reactive with defined regions of the T cell antigen receptor
IL172646A0 (en) Antibodies against interleukin -22 and uses therefor
WO1998050433A3 (en) Human monoclonal antibodies to epidermal growth factor receptor
EP1097945A3 (en) Monoclonal and chimeric antibody specific for human tumor necrosis factor
AU3208397A (en) Mutated nonactivating igg2 domains and anti-cd3 antibodies incorporating the same
SG44845A1 (en) Recombitant anti-vla4 antibody molecules
ZA946767B (en) Monocional antibodies having property of causing apoptosis.
WO1997022699A3 (en) Murine monoclonal anti-idiotype antibody 11d10 an methods of use thereof
WO2003026692A3 (en) Treatment of chronic joint inflammation using an antibody against the cd3 antigen complex
EP0866131A3 (en) Humanized anti-human fas antibody
ITRM920457A0 (it) Anticorpi monoclonali che riconoscono un epitopo della p-glicoproteinaumana.
MX9702422A (es) Anticuerpos recombinantes contra fas y adn para los mismos.
DK1021200T3 (da) Fremgangsmåder og præparater til behandling af rheumatoid arthritis
EP0723663A4 (en) HYBRIDOMA AND HUMANIZED MONOCLONAL ANTI-KC-4 ANTIBODIES, THESE ENCODING DNA AND RNS, KIT AND DIAGNOTIC AND THERAPEUTIC PROCEDURES
DK0610447T3 (da) CDw52-specifikt antistof til behandling af T-cellemedieret inflammation af leddene
NO894555D0 (no) Monoklonalt antistoff som spesifikt gjenkjenner n-glycolyl type gm2, hybridom som produserer antistoff og fremgangsmaate for fremstilling av hybridomet.
NO960683D0 (no) Monoklonalt antistoff som gjenkjenner interstitialcelle-overflateantigen
AU6162794A (en) Carcinoma associated antigen (ng1) monoclonal antibodies against ng1, methods of producing these antibodies and use therefor
IL161872A (en) Antibody stimulating il-1ra production
UA109629C2 (uk) Людське моноклональне антитіло проти cd20